Obesity remains a global health crisis, and while incretin-based therapies such as GLP-1 receptor agonists have transformed treatment, their primary reliance on appetite suppression and delayed gastric emptying alone often leads to a plateau in weight loss. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.